Literature DB >> 15198549

Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.

Jolyon P Mitchell1, Mark W Nagel, Kimberly J Wiersema, Cathy C Doyle.   

Abstract

The purpose of this research was to compare three different methods for the aerodynamic assessment of (1) chloroflurocarbon (CFC)--fluticasone propionate (Flovent), (2) CFC-sodium cromoglycate (Intal), and (3) hydrofluoroalkane (HFA)--beclomethasone dipropionate (Qvar) delivered by pressurized metered dose inhaler. Particle size distributions were compared determining mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction <4.7 microm aerodynamic diameter (FPF(<4.7 microm)). Next Generation Pharmaceutical Impactor (NGI)-size distributions for Flovent comprised finer particles than determined by Andersen 8-stage impactor (ACI) (MMAD = 2.0 +/- 0.05 micro m [NGI]; 2.8 +/- 0.07 microm [ACI]); however, FPF(<4.7 microm) by both impactors was in the narrow range 88% to 93%. Size distribution agreement for Intal was better (MMAD = 4.3 +/- 0.19 microm (NGI), 4.2 +/- 0.13 microm (ACI), with FPF(<4.7 microm) ranging from 52% to 60%. The Aerodynamic Particle Sizer (APS) undersized aerosols produced with either formulation (MMAD = 1.8 +/- 0.07 micro m and 3.2 +/- 0.02 micro m for Flovent and Intal, respectively), but values of FPF(<4.7 microm)from the single-stage impactor (SSI) located at the inlet to the APS (82.9% +/- 2.1% [Flovent], 46.4% +/- 2.4% [Intal]) were fairly close to corresponding data from the multi-stage impactors. APS-measured size distributions for Qvar (MMAD = 1.0 +/- 0.03 micro m; FPF(<4.7 micro m)= 96.4% +/- 2.5%), were in fair agreement with both NGI (MMAD = 0.9 +/- 0.03 micro m; FPF(<4.7 microm)= 96.7% +/- 0.7%), and ACI (MMAD = 1.2 +/- 0.02 microm, FPF(<4.7 microm)= 98% +/- 0.5%), but FPF(<4.7 microm) from the SSI (67.1% +/- 4.1%) was lower than expected, based on equivalent data obtained by the other techniques. Particle bounce, incomplete evaporation of volatile constituents and the presence of surfactant particles are factors that may be responsible for discrepancies between the techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15198549      PMCID: PMC2750647          DOI: 10.1208/pt040454

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols.

Authors:  J P Mitchell; M W Nagel
Journal:  J Aerosol Med       Date:  1999

2.  The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems.

Authors:  V A Marple; B A Olson; N C Miller
Journal:  J Aerosol Med       Date:  1998

3.  Cascade impactor data and the lognormal distribution: nonlinear regression for a better fit.

Authors:  Charles G Thiel
Journal:  J Aerosol Med       Date:  2002

4.  Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design.

Authors:  Virgil A Marple; Daryl L Roberts; Francisco J Romay; Nicholas C Miller; Keith G Truman; Michiel Van Oort; Bo Olsson; Michael J Holroyd; Jolyon P Mitchell; Dieter Hochrainer
Journal:  J Aerosol Med       Date:  2003

5.  Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration.

Authors:  Virgil A Marple; Bernard A Olson; Kumaragovindham Santhanakrishnan; Jolyon P Mitchell; Sharon C Murray; Buffy L Hudson-Curtis
Journal:  J Aerosol Med       Date:  2003

6.  Size analysis of a pressurized metered dose inhaler-delivered solution formulation by an Aerosizer-LD time-of-flight aerosol particle size spectrometer.

Authors:  Mark W Nagel; Kimberly J Wiersema; Sara Lou Bates; Jolyon P Mitchell
Journal:  J Aerosol Med       Date:  2002

7.  Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders.

Authors:  N Y Chew; D F Bagster; H K Chan
Journal:  Int J Pharm       Date:  2000-09-25       Impact factor: 5.875

8.  Pharmaceutical transition to non-CFC pressurized metered dose inhalers.

Authors:  A Cripps; M Riebe; M Schulze; R Woodhouse
Journal:  Respir Med       Date:  2000-06       Impact factor: 3.415

9.  Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer.

Authors:  J P Mitchell; M W Nagel; A D Archer
Journal:  J Aerosol Med       Date:  1999
  9 in total
  21 in total

Review 1.  Particle size analysis in pharmaceutics: principles, methods and applications.

Authors:  Boris Y Shekunov; Pratibhash Chattopadhyay; Henry H Y Tong; Albert H L Chow
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

Review 2.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

3.  Estimating the number of droplets and drug particles emitted from MDIs.

Authors:  Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2008-01-17       Impact factor: 3.246

4.  The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers.

Authors:  T Ehtezazi; I Saleem; I Shrubb; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

5.  Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Authors:  Terrence P Tougas; David Christopher; Jolyon P Mitchell; Helen Strickland; Bruce Wyka; Mike Van Oort; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

Review 6.  Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs).

Authors:  Jolyon Mitchell; Richard Bauer; Svetlana Lyapustina; Terrence Tougas; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-07-22       Impact factor: 3.246

7.  Airway deposition of nebulized gene delivery nanocomplexes monitored by radioimaging agents.

Authors:  Maria D I Manunta; Robin J McAnulty; Amy McDowell; Jing Jin; Deborah Ridout; John Fleming; Stephen E Bottoms; Livia Tossici-Bolt; Geoffrey J Laurent; Lorenzo Biassoni; Christopher O'Callaghan; Stephen L Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

8.  Evaluation of the TSI aerosol impactor 3306/3321 system using a redesigned impactor stage with solution and suspension metered-dose inhalers.

Authors:  Julie A Harris; Stephen W Stein; Paul B Myrdal
Journal:  AAPS PharmSciTech       Date:  2006-03-10       Impact factor: 3.246

9.  Novel simvastatin inhalation formulation and characterisation.

Authors:  Alaa S Tulbah; Hui Xin Ong; Paolo Colombo; Paul M Young; Daniela Traini
Journal:  AAPS PharmSciTech       Date:  2014-05-08       Impact factor: 3.246

10.  In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers.

Authors:  Mehra Haghi; Daniela Traini; Paul Young
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.